Conversely, mutations in higher-ranked kinases such as CHK2 (Table 1, rank 15) or PKD1 (rank 18) are rare (less than 1% of the PTC cases) and do not seem to contribute to thyroid cancer [35]. This evidence concerns the gene CHEK2 and thyroid gland carcinoma.